SCI Abstract

search
+
Disparities in Clinical Trial Enrollment– Focus on CAR-T and Bispecific Antibody Therapies
Disparities in Clinical Trial Enrollment– Focus on CAR-T and Bispecific Antibody Therapies
Recent studies show that unresolved disparities hinder enrollment to clinical trials, equitable distribution of treatments...
Monoclonal Gammopathy-Associated Neuropathy
Monoclonal Gammopathy-Associated Neuropathy
Peripheral neuropathy (PN) is more commonly seen in individuals with monoclonal gammopathies, especially in patients with ...
Navigating the Economic Burden of Multiple Myeloma: Insights into Cost-effectiveness of CAR-T and Bispecific Antibody Therapies
Navigating the Economic Burden of Multiple Myeloma: Insights into Cost-effectiveness of CAR-T and Bispecific Antibody Therapies
Multiple myeloma is a chronic malignancy and with evolving treatment options, understanding the economic burden and cost-e...
Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications
Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications
More than a decade following the discovery of Calreticulin (CALR) mutations as drivers of myeloproliferative neoplasms (MP...
Role of Population Based Studies in Advancing our Knowledge of Myelodysplastic Syndromes
Role of Population Based Studies in Advancing our Knowledge of Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) are myeloid neoplasms characterized by high molecular and genomic heterogeneity. According...
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma
The introduction of bispecific antibodies is one of the most significant recent advances in the treatment of relapsed/refr...
Systemic Mastocytosis: State of the Art
Systemic Mastocytosis: State of the Art
Since identification of Systemic mastocytosis (SM) as a distinct disease entity by the World Health Organisation (WHO), th...
JAK Inhibitors for Myelofibrosis: Strengths and Limitations
JAK Inhibitors for Myelofibrosis: Strengths and Limitations
The landscape of myelofibrosis (MF) has changed since the discovery of the JAK2 V617F mutation and subsequent development ...
Use of Patient-Centered Technology and Digital Interventions in Pediatric and Adult Patients with Hematologic Malignancies
Use of Patient-Centered Technology and Digital Interventions in Pediatric and Adult Patients with Hematologic Malignancies
As society continues to advance in technology, it is important to address how this advancement can impact and enhance pati...
Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities
Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities
Myelodysplastic syndromes/neoplasms (MDS) represent a diverse group of pathologically distinct diseases with varying progn...
Glucocorticoid Therapy in Acute Lymphoblastic Leukemia: Navigating Short-Term and Long-Term Effects and Optimal Regimen Selection
Glucocorticoid Therapy in Acute Lymphoblastic Leukemia: Navigating Short-Term and Long-Term Effects and Optimal Regimen Selection
Glucocorticoids are a mainstay in acute lymphoblastic leukemia treatment and lack of early response is predictive for over...
Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia
Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia
Waldenström macroglobulinemia is a rare non-Hodgkin lymphoma (NHL) characterized by lymphoplasmacytic bone marrow inf...
Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals
Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals
In this review, we aim to explore the optimal approach to patients presenting with eosinophilia, considering recent advanc...
Diagnosis and Management of Pulmonary Manifestations of Telomere Biology Disorders
Diagnosis and Management of Pulmonary Manifestations of Telomere Biology Disorders
Telomere biology disorders (TBD) are a group of genetic disorders characterized by premature shortening of telomeres, resu...
Adaptive and Maladaptive Clonal Hematopoiesis in Telomere Biology Disorders
Adaptive and Maladaptive Clonal Hematopoiesis in Telomere Biology Disorders
Telomere biology disorders (TBDs) are germline-inherited conditions characterized by reduction in telomerase function, acc...
Management of Patients with Early Myelofibrosis: A Discussion of Best Practices
Management of Patients with Early Myelofibrosis: A Discussion of Best Practices
Summarize best practices for management of patients with early myelofibrosis (MF). Myelofibrosis is a progressive myelopro...
Transplantation and Cellular Therapy for Older Adults—The MSK Approach
Transplantation and Cellular Therapy for Older Adults—The MSK Approach
Hematologic malignances more commonly affect older individuals and often present with advanced, higher risk disease than y...
How Do We Manage Chronic Lymphocytic Leukemia in India
How Do We Manage Chronic Lymphocytic Leukemia in India
Chronic lymphocytic leukemia was an ignored leukemia in India until a decade back, given its low prevalence and absence of...
Frontline Therapy of CLL—Changing Treatment Paradigms
Frontline Therapy of CLL—Changing Treatment Paradigms
The therapeutic landscape for chronic lymphocytic leukemia (CLL) has undergone a complete makeover following the introduct...
Telomere Biology Disorder: A Focus on Gastrointestinal and Hepatic Manifestations
Telomere Biology Disorder: A Focus on Gastrointestinal and Hepatic Manifestations
Telomere biology disorders (TBD) encompass several illnesses caused by underlying mutations in telomere maintenance leadin...
Blinatumomab in Practice
Blinatumomab in Practice
Acute lymphoblastic leukemia (ALL) is a rare hematologic neoplasm in adults, with most cases defined by pathology related ...
Novel Biomarkers and Molecular Targets in ALL
Novel Biomarkers and Molecular Targets in ALL
Acute lymphoblastic leukemia (ALL) is a widely heterogeneous disease in terms of genomic alterations, treatment options, a...
Unlocking the Potential of Artificial Intelligence in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Unlocking the Potential of Artificial Intelligence in Acute Myeloid Leukemia and Myelodysplastic Syndromes
This review aims to elucidate the transformative impact and potential of machine learning (ML) in the diagnosis, prognosis...
Measurable Residual Disease Monitoring in Lymphoma
Measurable Residual Disease Monitoring in Lymphoma
The utility of analyzing circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and disease in the bone marrow as ...
Experimental and Computational Approaches to Measure Telomere Length: Recent Advances and Future Directions
Experimental and Computational Approaches to Measure Telomere Length: Recent Advances and Future Directions
The length of telomeres, protective structures at the chromosome ends, is a well-established biomarker for pathological co...
Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders
Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders
Mature T/NK-cell neoplasms comprise a heterogeneous group of diseases with diverse clinical, histopathologic, immunophenot...
Genetic Counseling and Family Screening Recommendations in Patients with Telomere Biology Disorders
Genetic Counseling and Family Screening Recommendations in Patients with Telomere Biology Disorders
Telomere biology disorders (TBDs) encompass a spectrum of genetic diseases with a common pathogenesis of defects in telome...
NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition
NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition
The current review focuses on the preclinical development and clinical advances of natural killer (NK) cell therapeutics f...
An Update on the Management of Advanced Phase Chronic Myeloid Leukemia
An Update on the Management of Advanced Phase Chronic Myeloid Leukemia
While most patients with chronic myeloid leukemia (CML) present in a chronic phase and are expected to have a normal life ...
Central Nervous System Relapse in T and NK cell Lymphomas
Central Nervous System Relapse in T and NK cell Lymphomas
T and NK cell lymphomas are relatively rare and heterogeneous forms of non-Hodgkin lymphoma that are associated with high ...
Load More
format_indent_increase